advanced cancer
Conditions
Interventions
1:HIFU+PD-1 inhibitors
Sponsors
Mianyang Central Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: A. Aged >/=18 years; B. The patients were diagnosed as malignant tumor by histopathology; C. Immunotherapy (PD-1 antibody) after MDT discussion; D. ECoG PS score 0-2; E. At least one lesion can be ablated by HIFU, and more than one additional non continuous lesion can be monitored; F. There is no absolute contraindication of immunotherapy; G. Expected survival > 12 weeks.
Exclusion criteria
Exclusion criteria: A. The metastatic lesions were vertebral or intracranial, and there was no other lesion for HIFU ablation B. Serious heart, lung and kidney disease, unable to complete treatment; C. At the end of the life cycle, giving up the requirement for treatment; D. Unable to cooperate with treatment; E. It is expected that the skin pain response of the treatment access will be slow and loss; F. Patients who have previously received any immunotherapy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Toxicity;objective response rate;PFS;Changes of lymphocyte count and immune markers in peripheral blood; | — |
Secondary
| Measure | Time frame |
|---|---|
| Quality of life; | — |
Countries
China
Contacts
Public ContactDU Xiaobo
Mianyang Central Hospital
Outcome results
None listed